Cargando…
Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation
Extracellular vesicles (EVs) show promise for targeted drug delivery but face production challenges with low yields. Cell-derived nanovesicles (CDNVs) made by reconstituting cell membranes could serve as EV substitutes. In this study, CDNVs were generated from mesenchymal stem cells by extrusion. Th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609599/ https://www.ncbi.nlm.nih.gov/pubmed/37887902 http://dx.doi.org/10.3390/nano13202751 |
_version_ | 1785128051307184128 |
---|---|
author | Sayyed, Adil Ali Gondaliya, Piyush Yan, Irene K. Carrington, James Driscoll, Julia Moirangthem, Anuradha Patel, Tushar |
author_facet | Sayyed, Adil Ali Gondaliya, Piyush Yan, Irene K. Carrington, James Driscoll, Julia Moirangthem, Anuradha Patel, Tushar |
author_sort | Sayyed, Adil Ali |
collection | PubMed |
description | Extracellular vesicles (EVs) show promise for targeted drug delivery but face production challenges with low yields. Cell-derived nanovesicles (CDNVs) made by reconstituting cell membranes could serve as EV substitutes. In this study, CDNVs were generated from mesenchymal stem cells by extrusion. Their proteomic composition, in vitro and in vivo toxicity, and capacity for loading RNA or proteins were assessed. Compared with EVs, CDNVs were produced at higher yields, were comprised of a broader range of proteins, and showed no detrimental effects on cell proliferation, DNA damage, or nitric oxide production in vitro or on developmental toxicity in vivo. CDNVs could be efficiently loaded with RNA and engineered to modify surface proteins. The feasibility of generating immunomodulatory CDNVs was demonstrated by preparing CDNVs with enhanced surface expression of PD1, which could bind to PD-L1 expressing tumor cells, enhance NK and T cell degranulation, and increase immune-mediated tumor cell death. These findings demonstrate the adaptability and therapeutic promise of CDNVs as promising substitutes for natural EVs that can be engineered to enhance immunomodulation. |
format | Online Article Text |
id | pubmed-10609599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106095992023-10-28 Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation Sayyed, Adil Ali Gondaliya, Piyush Yan, Irene K. Carrington, James Driscoll, Julia Moirangthem, Anuradha Patel, Tushar Nanomaterials (Basel) Article Extracellular vesicles (EVs) show promise for targeted drug delivery but face production challenges with low yields. Cell-derived nanovesicles (CDNVs) made by reconstituting cell membranes could serve as EV substitutes. In this study, CDNVs were generated from mesenchymal stem cells by extrusion. Their proteomic composition, in vitro and in vivo toxicity, and capacity for loading RNA or proteins were assessed. Compared with EVs, CDNVs were produced at higher yields, were comprised of a broader range of proteins, and showed no detrimental effects on cell proliferation, DNA damage, or nitric oxide production in vitro or on developmental toxicity in vivo. CDNVs could be efficiently loaded with RNA and engineered to modify surface proteins. The feasibility of generating immunomodulatory CDNVs was demonstrated by preparing CDNVs with enhanced surface expression of PD1, which could bind to PD-L1 expressing tumor cells, enhance NK and T cell degranulation, and increase immune-mediated tumor cell death. These findings demonstrate the adaptability and therapeutic promise of CDNVs as promising substitutes for natural EVs that can be engineered to enhance immunomodulation. MDPI 2023-10-12 /pmc/articles/PMC10609599/ /pubmed/37887902 http://dx.doi.org/10.3390/nano13202751 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sayyed, Adil Ali Gondaliya, Piyush Yan, Irene K. Carrington, James Driscoll, Julia Moirangthem, Anuradha Patel, Tushar Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation |
title | Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation |
title_full | Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation |
title_fullStr | Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation |
title_full_unstemmed | Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation |
title_short | Engineering Cell-Derived Nanovesicles for Targeted Immunomodulation |
title_sort | engineering cell-derived nanovesicles for targeted immunomodulation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609599/ https://www.ncbi.nlm.nih.gov/pubmed/37887902 http://dx.doi.org/10.3390/nano13202751 |
work_keys_str_mv | AT sayyedadilali engineeringcellderivednanovesiclesfortargetedimmunomodulation AT gondaliyapiyush engineeringcellderivednanovesiclesfortargetedimmunomodulation AT yanirenek engineeringcellderivednanovesiclesfortargetedimmunomodulation AT carringtonjames engineeringcellderivednanovesiclesfortargetedimmunomodulation AT driscolljulia engineeringcellderivednanovesiclesfortargetedimmunomodulation AT moirangthemanuradha engineeringcellderivednanovesiclesfortargetedimmunomodulation AT pateltushar engineeringcellderivednanovesiclesfortargetedimmunomodulation |